Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Alger Weatherbie Specialized Growth Fund H. George Dai, Joshua D. Bennett | “Acadia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines that address unmet needs in central nervous system (CNS) disorders. Its products include Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis, and Daybue, for Rett syndrome—a rare genetic disorder that affects brain development in children. Shares contributed positively during the quarter after the company reported better-than-expected third-quarter 2025 results that reinforced momentum across its two commercial franchises: Nuplazid saw solid demand and new patient activity, while Daybue posted strong referral trends. Sentiment was further supported late in the quarter by the FDA's approval of DAYBUE STIX, a new powder formulation, underscoring continued franchise investment. BSD Analysis: ACADIA is a CNS-focused biopharma anchored by Nuplazid, with growing emphasis on mood disorders and neuropsychiatric conditions. The company is working to diversify beyond a single-asset narrative through pipeline development and lifecycle management. Commercial execution has been uneven, but cash flow supports continued R&D investment. CNS drug development carries higher clinical risk, but successful differentiation commands premium pricing. ACADIA's value hinges on pipeline readouts and label expansion. It's no longer a pure binary biotech, but visibility is still limited. A mid-risk CNS growth story with optionality.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Alger Weatherbie Specialized Growth Fund H. George Dai, Joshua D. Bennett | “Acadia is a biopharmaceutical company that focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system (CNS) disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis, and Daybue, designed for treating Rett Syndrome—a rare genetic disorder that affects brain development in children. Shares of Acadia contributed positively during the quarter after the company delivered better-than-expected fiscal first-quarter revenue driven by Nuplazid, which management highlighted is seeing the highest rate of new patient starts since 2020. Additionally, management reaffirmed its full-year 2025 revenue guidance, noting Daybue sales growth now appears more attainable following sequential patient growth after two quarters of stability, combined with consistent patient retention. Encouragingly, prescription growth from community-based healthcare providers—where most patients receive treatment—accelerated even prior to the completion of a roughly 30% salesforce expansion in the first quarter. With approximately 67% of Rett syndrome patients yet to try Daybue, we believe the product holds significant long-term growth potential. BSD Analysis: Acadia has quietly transformed from a one-drug story into a diversified CNS pipeline with serious commercial momentum. Nuplazid remains a meaningful cash generator, but the real growth engine is Daybue — one of the most significant rare-disease launches in years. Acadia's pipeline expansion into neuropsychiatric and neurological disorders gives it multi-shot optionality. Margins are improving, commercial execution is strong, and regulatory risk is lower than most mid-cap biotechs. The market is still pricing Acadia like a single-asset company — that window is closing fast.” | BULL | Q2 2025 Jul 7, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
